Ezio Baraldi

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham et al. · The Lancet · 2004 · 683 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?

Bregt S Kappelhoff, Frank van Leth, Patrick Robinson et al. · Antiviral Therapy · 2005 · 160 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial

Stephen E. Goldstone, Anna R. Giuliano, Joel M. Palefsky et al. · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · 2021 · 54 citations · Full text

Veterinary Medicine, Immunology, Immunization +11

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 32 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS

Eduardo Arathoon, Stefan Schneider, Ezio Baraldi et al. · International Journal of STD & AIDS · 2013 · 20 citations

Pharmacy, Pharmacology, Pharmacotherapy +17